<DOC>
	<DOCNO>NCT02346760</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics single subcutaneous dose UB-621 healthy volunteer .</brief_summary>
	<brief_title>Study Evaluate Safety , Tolerability , Pharmacokinetics UB-621 Healthy Volunteers</brief_title>
	<detailed_description>This phase I , open-label , single dose , dose escalation study healthy volunteer . Eligible volunteer sequentially enrol four escalating-dose cohort study site . After administration single subcutaneous dose UB-621 , subject follow 70 day monitor safety , tolerability , pharmacokinetics parameter .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<criteria>With age 20 55 year . With clinically relevant abnormality vital sign , clinical laboratory test screen visit judge investigator . Body weight : &lt; 85 kg . Subject sign write informed consent form . With significant active infection ( acute chronic ) within 28 day prior screen visit . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic allergic disease , clinical finding within 3 month prior screen visit . Positive serology HIV antibody , HCV antibody HBV surface antigen . Female subject breastfeed , pregnant , plan become pregnant study period . The clinical investigator considers subject condition participate study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>